BIRC5 and cancer: Survivin immunostaining was absent in 61% of cancers with TMPRSS2:ERG fusion detected by IHC and 63% of cancers detected by FISH, but only in 32% of cancers without ERG staining and 33% of cancers without ERG rearrangements detected by FISH (P < .0001 each; Figure 2).